Company Information

    Tactiva Therapeutics was founded on January 2016. The company is based in Buffalo, NY, USA . The number of employees in Tactiva Therapeutics is less than 10. Tactiva therapeutics is a development stage immuno-oncology company

    Here is how Tactiva Therapeutics describes itself: "Tactiva Therapeutics is an immuno-oncology company specializing in potent cancer immunotherapy using a dual T cell receptor approach."
      If you are the founder or part of the founding team, please tell the world your story


          Funding & investors

          Tactiva Therapeutics has received 1 rounds of venture funding. The total funding amount is around $35M.

            Similar Companies [beta]

              Venture Categories

                Active Venture Investors




                  Venture Competitors

                    News

                        Tactiva Therapeutics - Blog

                          • Tactiva Therapeutics Secures $35 Million Series A Financing to Pursue Clinical Development of DEACT Platform

                          • Abstract Buffalo, NY, December 3, 2018 – Tactiva Therapeutics, development stage immuno-oncology company with a unique approach to adoptive T-cell therapy, announced today it has secured a $35 million Series […]The post Tactiva Therapeutics Secures $35 Million Series A Financing to Pursue Clinical Development of DEACT Platform appeared first on Tactiva Therapeutics.
                          • Tactiva Therapeutics Announces License to Oncolytic Vaccinia Virus Armed With CXCR4 Antagonist for Treatment of Ovarian Cancer

                          • Abstract Buffalo, NY based Tactiva Therapeutics, Inc. announced they’ve licensed new intellectual property from the Roswell Park Cancer Institute Corporation that covers the use of the Oncolytic Vaccinia Virus (OVV) […]The post Tactiva Therapeutics Announces License to Oncolytic Vaccinia Virus Armed With CXCR4 Antagonist for Treatment of Ovarian Cancer appeared first on Tactiva Therapeutics.
                          • Tactiva Therapeutics Co-Founder Kunle Odunsi Elected to National Academy of Medicine

                          • Abstract BUFFALO, N.Y., October 16, 2018 — Tactiva Therapeutics, a development stage company targeting a broad range of cancers, announced today that its co-founder Kunle Odunsi, M.D., Ph.D., FRCOG, FACOG, […]The post Tactiva Therapeutics Co-Founder Kunle Odunsi Elected to National Academy of Medicine appeared first on Tactiva Therapeutics.
                          • Roswell Park introduces “Tactiva Therapeutics” as new Biotech Spinoff Company

                          • BUFFALO, N.Y.(WKBW) - Lieutenant Governor Kathy Hochul, Dr. Candace Johnson and a special team of doctors at Roswell Park announced the launch of a new innovative Immunotherapy Biotech Company called, Tactiva Therapeutics in front of a packed house inside Roswell's Research Center.Tactiva will develop the latest science to lead even more effective approaches at fighting and treating the most aggressive forms of cancer. In addition, ...The post Roswell Park introduces “Tactiva Therapeutics” as new Biotech Spinoff Company appeared first on Tactiva Therapeutics.

                          Share:                    

                            Startup - Venture Capital - Innovation

                            Ventures Media is one of the largest startup and venture capital communities for startup and venture capital funding information and analysis.

                            Leave a Reply

                            Your email address will not be published. Required fields are marked *